Epicardial adipose tissue is associated with increased systolic pulmonary artery pressure in patients with chronic obstructive pulmonary disease

Pulmonary hypertension (PHT) is one of the essential predictors of mortality in chronic obstructive pulmonary disease (COPD). It is thought that PHT is due to vasoconstriction secondary to hypoxia caused by airway obstruction in COPD patients; however, loss of capillary bed with emphysema, inflammation, and endothelial dysfunction may also play a role in the development of PHT. Epicardial adipose tissue (EAT) has a role as a metabolically active endocrine organ and secretes various proinflammatory cytokines. We hypothesized that EAT thickness in COPD patients might be associated with the systolic pulmonary arterial pressure (PAPs) level, and we aimed to test it.

[1]  G. Hindricks,et al.  Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205]. , 2019, Atherosclerosis.

[2]  Li Sun,et al.  Metoprolol Inhibits Profibrotic Remodeling of Epicardial Adipose Tissue in a Canine Model of Chronic Obstructive Sleep Apnea , 2019, Journal of the American Heart Association.

[3]  Shing‐Jong Lin,et al.  Association between echocardiographic epicardial fat thickness and circulating endothelial progenitor cell level in patients with stable angina pectoris , 2017, Clinical cardiology.

[4]  P. Paré,et al.  Increased Epicardial Adipose Tissue Is Associated with the Airway Dominant Phenotype of Chronic Obstructive Pulmonary Disease , 2016, PloS one.

[5]  B. Lipworth,et al.  The role of pulmonary arterial stiffness in COPD , 2015, Respiratory medicine.

[6]  Gianluca Iacobellis,et al.  Local and systemic effects of the multifaceted epicardial adipose tissue depot , 2015, Nature Reviews Endocrinology.

[7]  J. Wells,et al.  Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD , 2013, International Journal of COPD.

[8]  B. Celli,et al.  Epicardial Adipose Tissue in Patients with Chronic Obstructive Pulmonary Disease , 2013, PloS one.

[9]  D. Moertl,et al.  Pulmonary artery pulse wave velocity in idiopathic pulmonary arterial hypertension. , 2013, The Canadian journal of cardiology.

[10]  Khaled Z. Abd-Elmoniem,et al.  A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial , 2013, Trials.

[11]  J. Loscalzo,et al.  Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension , 2012, Circulation.

[12]  W. Qin,et al.  Assessment of the right ventricular function in patients with chronic obstructive pulmonary disease using MRI , 2011, Acta radiologica.

[13]  S. Mueller,et al.  Xanthine Oxidase Inhibition Attenuates Endothelial Dysfunction Caused by Chronic Intermittent Hypoxia in Rats , 2011, Respiration.

[14]  Samir R. Thadani,et al.  Epicardial fat volume in patients with left ventricular systolic dysfunction. , 2011, The American journal of cardiology.

[15]  C. Lang,et al.  Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[16]  N. Voelkel,et al.  COPD/emphysema: The vascular story , 2011, Pulmonary circulation.

[17]  H. Willens,et al.  Echocardiographic epicardial fat: a review of research and clinical applications. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[18]  R. Naeije,et al.  Pulmonary hypertension in COPD , 2008, European Respiratory Journal.

[19]  Mathias Prokop,et al.  Relation of epicardial and pericoronary fat to coronary atherosclerosis and coronary artery calcium in patients undergoing coronary angiography. , 2008, The American journal of cardiology.

[20]  Crystal Kantores,et al.  Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[21]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[22]  H. Sacks,et al.  Human epicardial adipose tissue: a review. , 2007, American heart journal.

[23]  R. Tkacova,et al.  Systemic inflammation in patients with COPD and pulmonary hypertension. , 2006, Chest.

[24]  B. Housset,et al.  Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. , 2006, Proceedings of the American Thoracic Society.

[25]  J. Marcus,et al.  Early changes of cardiac structure and function in COPD patients with mild hypoxemia. , 2005, Chest.

[26]  J. Gardin,et al.  American Society of Echocardiography recommendations for use of echocardiography in clinical trials. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[27]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[28]  W. Haynes,et al.  Role of xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers. , 2004, The American journal of cardiology.

[29]  K. Shirato,et al.  Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways , 2003, European Respiratory Journal.

[30]  T. Veel,et al.  Allopurinol inhibits hypoxic pulmonary vasoconstriction. Role of toxic oxygen metabolites , 1990, Acta anaesthesiologica Scandinavica.

[31]  A. Ducoloné,et al.  Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. , 1981, Thorax.